Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cynata Therapeutics Ltd V.CYP


Primary Symbol: CYYNF

Healthcare Biotechnology
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.


OTCPK:CYYNF - Post by User

Cynata Therapeutics Ltd > Good news for all Clay miners!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(26)
•••
Comment by GarryJan1on Jan 26, 2021 11:01am
134 Views
Post# 32387081

RE:Good news for all Clay miners!!

RE:Good news for all Clay miners!! If no Sulfuric acid plant is needed thats huge, Cypress also has to try this method.

https://www.accesswire.com/625753/Noram-Provides-Successful-Update-on-Chloride-Based-Leaching-for-Lithium-Clay-Extraction-95-Li-Into-Solution

In addition, this may allow us to forego a building a sulfuric acid plant on site, which is a very significant part of the Capex of other lithium claystone projects in Nevada.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities